Transgene SA (TRGNF)
USD 1.59
(0.0%)
USD 1.59
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -30.04 Million EUR | -18.35% |
| 2022 | -29.9 Million EUR | -27.12% |
| 2021 | -23.52 Million EUR | 1.95% |
| 2020 | -23.99 Million EUR | 5.74% |
| 2019 | -25.45 Million EUR | -445.47% |
| 2018 | 7.36 Million EUR | 126.27% |
| 2017 | -28.04 Million EUR | -23.73% |
| 2016 | -22.66 Million EUR | 36.71% |
| 2015 | -35.8 Million EUR | 23.7% |
| 2014 | -46.93 Million EUR | -13.92% |
| 2013 | -41.19 Million EUR | 2.22% |
| 2012 | -42.13 Million EUR | 6.01% |
| 2011 | -44.82 Million EUR | -29.54% |
| 2010 | -34.6 Million EUR | -26.6% |
| 2009 | -27.33 Million EUR | -24.51% |
| 2008 | -21.95 Million EUR | -194.37% |
| 2007 | -7.45 Million EUR | 66.87% |
| 2006 | -22.51 Million EUR | 0.0% |
| 2004 | -21.67 Million EUR | 1.21% |
| 2003 | -21.93 Million EUR | -7.64% |
| 2002 | -20.37 Million EUR | 16.22% |
| 2001 | -24.32 Million EUR | 1.47% |
| 2000 | -24.68 Million EUR | -13.27% |
| 1999 | -21.79 Million EUR | -57.01% |
| 1998 | -13.88 Million EUR | 5.04% |
| 1997 | -14.61 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -8.24 Million EUR | -12.1% |
| 2024 Q2 | -8.24 Million EUR | 0.0% |
| 2023 Q4 | -7.35 Million EUR | -0.24% |
| 2023 FY | -35.39 Million EUR | -18.35% |
| 2023 Q1 | -7.66 Million EUR | 58.18% |
| 2023 Q2 | -17.66 Million EUR | -130.41% |
| 2023 Q3 | -7.33 Million EUR | 58.45% |
| 2022 Q4 | -18.33 Million EUR | -143.43% |
| 2022 FY | -29.9 Million EUR | -27.12% |
| 2022 Q2 | -18.62 Million EUR | -151.03% |
| 2022 Q3 | -7.53 Million EUR | 59.55% |
| 2022 Q1 | -7.41 Million EUR | 43.81% |
| 2021 Q1 | -6.71 Million EUR | 58.12% |
| 2021 Q3 | -5.13 Million EUR | 69.92% |
| 2021 FY | -23.52 Million EUR | 1.95% |
| 2021 Q2 | -17.05 Million EUR | -153.99% |
| 2021 Q4 | -13.2 Million EUR | -157.25% |
| 2020 Q3 | -6.46 Million EUR | 56.51% |
| 2020 Q1 | -5.69 Million EUR | 62.24% |
| 2020 Q2 | -14.87 Million EUR | -161.0% |
| 2020 Q4 | -16.03 Million EUR | -147.92% |
| 2020 FY | -23.99 Million EUR | 5.74% |
| 2019 Q2 | -16.77 Million EUR | -149.92% |
| 2019 Q1 | -6.71 Million EUR | 10.29% |
| 2019 Q3 | -5.98 Million EUR | 64.33% |
| 2019 Q4 | -15.09 Million EUR | -152.15% |
| 2019 FY | -25.45 Million EUR | -445.47% |
| 2018 FY | 7.36 Million EUR | 126.27% |
| 2018 Q1 | -6.62 Million EUR | -14.54% |
| 2018 Q2 | -6.62 Million EUR | 0.0% |
| 2018 Q3 | -7.48 Million EUR | -12.95% |
| 2018 Q4 | -7.48 Million EUR | 0.0% |
| 2017 FY | -28.04 Million EUR | -23.73% |
| 2017 Q4 | -5.78 Million EUR | 0.0% |
| 2017 Q2 | -8.2 Million EUR | 0.0% |
| 2017 Q1 | -8.2 Million EUR | -43.19% |
| 2017 Q3 | -5.78 Million EUR | 29.54% |
| 2016 Q2 | -5.47 Million EUR | 0.0% |
| 2016 FY | -22.66 Million EUR | 36.71% |
| 2016 Q4 | -5.73 Million EUR | 0.0% |
| 2016 Q3 | -5.73 Million EUR | -4.66% |
| 2016 Q1 | -5.47 Million EUR | 21.59% |
| 2015 FY | -35.8 Million EUR | 23.7% |
| 2015 Q4 | -6.98 Million EUR | 0.0% |
| 2015 Q2 | -7.14 Million EUR | 0.0% |
| 2015 Q3 | -6.98 Million EUR | 2.22% |
| 2015 Q1 | -7.14 Million EUR | 3.84% |
| 2014 Q4 | -7.42 Million EUR | 0.0% |
| 2014 Q3 | -7.42 Million EUR | 24.12% |
| 2014 Q1 | -9.79 Million EUR | -3.31% |
| 2014 FY | -46.93 Million EUR | -13.92% |
| 2014 Q2 | -9.79 Million EUR | 0.0% |
| 2013 Q2 | -11.11 Million EUR | 0.0% |
| 2013 Q4 | -9.47 Million EUR | 0.0% |
| 2013 Q3 | -9.47 Million EUR | 14.73% |
| 2013 FY | -41.19 Million EUR | 2.22% |
| 2013 Q1 | -11.11 Million EUR | 0.0% |
| 2012 FY | -42.13 Million EUR | 6.01% |
| 2011 FY | -44.82 Million EUR | -29.54% |
| 2010 FY | -34.6 Million EUR | -26.6% |
| 2009 FY | -27.33 Million EUR | -24.51% |
| 2008 FY | -21.95 Million EUR | -194.37% |
| 2007 FY | -7.45 Million EUR | 66.87% |
| 2006 FY | -22.51 Million EUR | 0.0% |
| 2005 Q1 | 1.01 Million EUR | 104.32% |
| 2005 Q2 | -4.92 Million EUR | -585.77% |
| 2004 Q3 | 832.52 Thousand EUR | 115.85% |
| 2004 Q2 | -5.25 Million EUR | 6.7% |
| 2004 Q1 | -5.62 Million EUR | 17.1% |
| 2004 Q4 | -23.47 Million EUR | -2919.17% |
| 2004 FY | -21.67 Million EUR | 1.21% |
| 2003 Q2 | -5.4 Million EUR | -5.18% |
| 2003 FY | -21.93 Million EUR | -7.64% |
| 2003 Q3 | -4.59 Million EUR | 15.06% |
| 2003 Q1 | -5.14 Million EUR | -4.92% |
| 2003 Q4 | -6.79 Million EUR | -47.81% |
| 2002 Q2 | -5.32 Million EUR | 1.33% |
| 2002 FY | -20.37 Million EUR | 16.22% |
| 2002 Q1 | -5.4 Million EUR | 25.18% |
| 2002 Q3 | -4.84 Million EUR | 8.98% |
| 2002 Q4 | -4.9 Million EUR | -1.05% |
| 2001 Q2 | -5.99 Million EUR | -2.64% |
| 2001 FY | -24.32 Million EUR | 1.47% |
| 2001 Q4 | -7.21 Million EUR | -37.25% |
| 2001 Q3 | -5.25 Million EUR | 12.26% |
| 2001 Q1 | -5.83 Million EUR | -12.67% |
| 2000 Q1 | -7.07 Million EUR | 72.01% |
| 2000 FY | -24.68 Million EUR | -13.27% |
| 2000 Q4 | -5.18 Million EUR | 35.63% |
| 2000 Q3 | -8.05 Million EUR | -85.18% |
| 2000 Q2 | -4.34 Million EUR | 38.52% |
| 1999 Q1 | 1.48 Million EUR | 105.89% |
| 1999 FY | -21.79 Million EUR | -57.01% |
| 1999 Q2 | 1.26 Million EUR | -14.94% |
| 1999 Q4 | -25.26 Million EUR | -3463.79% |
| 1999 Q3 | 751.18 Thousand EUR | -40.41% |
| 1998 Q4 | -25.14 Million EUR | -5986.12% |
| 1998 Q1 | 7.94 Million EUR | 0.0% |
| 1998 Q2 | 646.03 Thousand EUR | -91.87% |
| 1998 Q3 | 427.27 Thousand EUR | -33.86% |
| 1998 FY | -13.88 Million EUR | 5.04% |
| 1997 FY | -14.61 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 58.144% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 711.356% |
| SQZ Biotechnologies Company | -75.82 Million USD | 60.373% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -68.359% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 136.709% |
| Mesoblast Limited | -84.14 Million USD | 64.292% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1856.122% |
| Genus plc | 6.4 Million USD | 569.484% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 408.413% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -3126.073% |
| Marizyme, Inc. | -34.08 Million USD | 11.851% |
| ContraFect Corporation | -56.88 Million USD | 47.183% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -259.844% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -559.688% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2043.166% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -954.093% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -992.285% |
| MultiCell Technologies, Inc. | -722.81 USD | -4156870.712% |
| Accustem Sciences Inc. | -3.74 Million USD | -702.019% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 49.064% |
| EV Biologics, Inc. | -483.06 Thousand USD | -6120.113% |
| Q BioMed Inc. | -3.44 Million USD | -772.036% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 948.785% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -7612.863% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -1043.549% |
| Biomind Labs Inc. | -1 Million USD | -2876.12% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -515.775% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -351.969% |
| Skye Bioscience, Inc. | -13.67 Million USD | -119.774% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -1412.576% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -100217.174% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -495.641% |
| IMV Inc. | -38.67 Million USD | 22.302% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -89.335% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -1454.737% |
| GB Sciences, Inc. | -1.42 Million USD | -2015.228% |
| Alpha Cognition Inc. | -9.7 Million USD | -209.584% |
| HST Global, Inc. | -140.9 Thousand USD | -21223.994% |
| CSL Limited | 3.7 Billion USD | 100.812% |
| Halberd Corporation | -75.05 Thousand USD | -39935.976% |
| Enzolytics Inc. | -2.14 Million USD | -1298.315% |
| Resverlogix Corp. | -12.74 Million USD | -135.681% |
| Affymax, Inc. | -15.04 Million USD | -99.701% |
| SYBLEU INC | -149.18 Thousand USD | -20041.44% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -848.371% |
| argenx SE | -425.04 Million USD | 92.931% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 45.869% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -2778.065% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1802.486% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -782.443% |
| AVAX Technologies, Inc. | 6.69 Million USD | 548.94% |
| Zenith Capital Corp. | -8.94 Million USD | -235.983% |
| Genscript Biotech Corporation | -415.79 Million USD | 92.774% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -172375.748% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -1123.752% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -17419.142% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 45.342% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -935.657% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -2953.392% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -1511.644% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -2292.277% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1398.785% |
| BioStem Technologies, Inc. | -7.77 Million USD | -286.259% |
| ONE Bio Corp. | 13.68 Million USD | 319.617% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -16456.189% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2149.985% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -2571.068% |
| Agentix Corp. | -1.37 Million USD | -2090.404% |
| LadRx Corporation | -3.82 Million USD | -685.825% |
| Cell Source, Inc. | -4.32 Million USD | -594.673% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -7131.894% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -4273.972% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -4273.972% |
| NovAccess Global Inc. | -2.46 Million USD | -1118.076% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -929.203% |
| Itoco Inc. | -919.14 Thousand USD | -3169.034% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -608.921% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -2585.165% |
| Kadimastem Ltd | -3.04 Million USD | -888.307% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -11380.327% |
| CytoDyn Inc. | -18.05 Million USD | -66.392% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -119276.242% |
| Mobile Lads Corp. | -554.55 Thousand USD | -5318.267% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -13552.887% |
| Qrons Inc. | -643.67 Thousand USD | -4568.024% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -5220.662% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -1247.472% |
| Rebus Holdings, Inc. | -664 Thousand USD | -4425.151% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -1554.279% |
| International Stem Cell Corporation | -663 Thousand USD | -4431.976% |
| Bioxytran, Inc. | -3.82 Million USD | -686.54% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -56980.167% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -147623.697% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 17.148% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -1757.046% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -3983.388% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -865.831% |
| Neutra Corp. | -229.48 Thousand USD | -12993.173% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -71.315% |
| PureTech Health plc | -146.19 Million USD | 79.448% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -39.811% |
| IXICO plc | -1.43 Million USD | -1990.953% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -216.584% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 75.332% |
| CSL Limited | 3.81 Billion USD | 100.788% |
| Cellectis S.A. | -108.85 Million USD | 72.398% |